Facebook
X
LinkedIn
ForwardMasters of Pediatric Dermatology
Activity Overview
General Session:
Managing the diverse range of dermatologic conditions in the pediatric population, including acne vulgaris, alopecia areata, atopic dermatitis, chronic urticaria, epidermolysis bullosa, hidradenitis suppurativa, molluscum contagiosum, plaque psoriasis, seborrheic dermatitis, tuberous sclerosis complex, and vitiligo, continues to present unique challenges for both patients and health care professionals (HCPs). To address these complexities, HCPs urgently require comprehensive education on current guidelines, advanced diagnostic tools, critical efficacy and safety data from clinical trials involving new and emerging therapeutic agents, and practical clinical pearls for optimizing the care of younger patients. The 34th annual Masters of Pediatric Dermatology Symposium is specifically designed to guide attendees through the latest evidence-based treatment approaches, protocols, procedures, and tools, ultimately empowering them to deliver superior and more personalized dermatologic care to children and adolescents.
Managing EB: Focus on RDEB:
Epidermolysis bullosa (EB) is a group of rare, inherited disorders characterized by extreme skin fragility, chronic blistering, and a significantly diminished quality of life. While the genetic complexity of EB has historically made management difficult, recent breakthroughs, including FDA-approved gene therapies, cellular sheets, and topical gel, have transformed the treatment landscape. This live session at the 2026 Masters of Pediatric Dermatology meeting offers expert guidance on integrating these evidence-based therapies into clinical practice, with a specific focus on optimizing care for recessive dystrophic EB.
Barrier to Breakthrough: Mastering Targeted Topicals for Skin Barrier Repair in Pediatric AD:
Atopic dermatitis (AD) is a chronic inflammatory condition that is exacerbated by disruption of the skin barrier, yet management remains challenging due to the limitations of traditional agents and the need for optimal safety and tolerability in pediatric populations. The recently expanded indications for PDE4 inhibitors, JAK inhibitors, and AhR agonists, represent a major therapeutic shift by offering non-steroidal treatment options. Health care professionals who treat pediatric patients with AD must be familiar with the latest clinical efficacy and safety data to effectively leverage these new treatments. This in-line session, to be held at the 2026 Masters of Pediatric Dermatology, will educate participants on AD pathophysiology and the latest clinical data for targeted topicals in pediatric patients, providing expert-guided strategies to optimize management.
Target Audience
The Masters of Pediatric Dermatology symposium is designed for an audience of US-based dermatologists, pediatricians, pediatric dermatologists, nurses and allied health providers (nurse practitioners and physician assistants).
Learning Objectives
General Session:
- Summarize topline clinical trial data for new therapies for acne vulgaris.
- Analyze clinical safety and efficacy data for current and emerging alopecia areata therapies for adolescents.
- Examine the clinical efficacy and safety data for established and emerging therapies for pediatric patients with atopic dermatitis.
- Evaluate the clinical efficacy and safety data for current and emerging pediatric chronic urticaria therapies.
- Analyze the clinical data for new epidermolysis bullosa therapies to facilitate appropriate treatment selection for a given disease subtype.
- Describe current hidradenitis suppurativa treatment strategies for pediatric and adolescent patients based on clinical efficacy and safety data for current and emerging therapies.
- Evaluate the clinical efficacy and safety data for emerging treatment options for pediatric molluscum.
- Critically evaluate the clinical data for current and emerging therapies for pediatric plaque psoriasis.
- Evaluate the clinical data for current and emerging treatment options for pediatric chronic seborrheic dermatitis.
- Review the clinical data for modern and emerging treatment options, including mTOR inhibitors, for managing tuberous sclerosis complex-related symptoms.
- Assess the clinical data for current and emerging pediatric vitiligo therapies.
Managing EB: Focus on RDEB:
- Differentiate the clinical and genetic features of recessive dystrophic epidermolysis bullosa from other EB subtypes to appropriately rationalize the selection of targeted therapies.
- Evaluate the clinical trial data and practical application techniques for cell-based gene therapy and other emerging treatments for RDEB as part of a multidisciplinary management strategy.
Barrier to Breakthrough: Mastering Targeted Topicals for Skin Barrier Repair in Pediatric AD:
- Describe the role of skin barrier dysfunction in atopic dermatitis pathogenesis to rationalize selection of appropriate topical therapy for pediatric patients.
- Critically analyze clinical data for new targeted topical therapies to inform treatment selection in pediatric atopic dermatitis.
Commercial Support
This activity is supported by educational grants from Almirall, LLC, Genentech, Inc., Incyte Corporation, and Pfizer Inc.
Managing EB: Focus on RDEB session is supported by educational grant from Abeona Therapeutics Inc.
Barrier to Breakthrough: Mastering Targeted Topicals for Skin Barrier Repair in Pediatric AD session is supported by educational grant from Arcutis Biotherapeutics, Inc.
DISCLOSURES | ||
Name | Relationship | Commercial Interest |
Adelaide Hebert, MD | Advisor | Pfizer, Arcutis, Incyte, Dermavant/Organon, Sun Pharma, Lilly, Ortho Dermatologics, Takeda, Oness |
Consultant | Pfizer, Arcutis, Dermavant, Organon/Dermavant, Incyte, Lilly, Takeda, Ortho Dermatologics, Galderma | |
Researcher | Pfizer, Organon, Oneness, Takeda, Janssen, Arcutis, Amgen, Abbvie, Galderma | |
Anna Bruckner, MD | Consultant | Abeona Therapeutics, Chiesi, TwiBio |
Independent contractor (including contracted research) | Castle Creek, Rheacell, TwiBio | |
Antonella Tosti, MD | Advisor | DS Laboratories, Almirall, Tirthy Madison, Eli Lilly, Pfizer, Myovant, Bristol Myers Squibb , Ortho Dermatologics, Sun Pharmaceuticals, Abbvie, WellBeauty Company LLC, L'Oreal/Vichy USA, Amgen |
Antonio Torrelo, MD | Advisor | Lilly, Pfizer |
Speaker | Viatris, Lilly | |
Catherine Doernbrack, MSN, RN, CPNP-PC | N/A | Nothing to disclose |
Fernanda Schmidt, MD | Researcher | Timber Pharmaceutical, Anterogen Co |
Jennifer Hsiao, MD | Consultant | Consultant/Advisory board: AbbVie, Aclaris, Boehringer Ingelheim, Galderma, Incyte, Insmed, Moonlake, Leo Pharma, Navigator Medicines, Novartis, Oruka Therapeutics, Pfizer, Sanofi, Regeneron, UCB |
Researcher | Investigator: Amgen, AstraZeneca, Incyte, Novartis | |
Speaker | AbbVie, Galderma, Novartis, Sanofi, Regeneron, UCB | |
Jonette Keri, MD, PhD | N/A | Nothing to disclose. |
Karan Lal, DO | Consultant | Sanofi, Abbvie |
Speaker | Abbvie, Galderma, Pfizer, Amgen, Sanofi, Regeneron, Incyte, Botanix, Sun, Aerolase, Lilly | |
Kristina Derrick, MD | Advisor | Chiesi |
Consultant | Colgate, Kenvue, Veradermics | |
Speaker | Verrica, Chiesi | |
Latanya Benjamin, MD | N/A | Nothing to disclose. |
Lawrence Schachner, MD | Investigator | Astellas, Berg Pharma, Celgene, Ferndale Labs, Lilly, Medimetriks, Novartis, Organogensis Inc., Sciton |
Consultant | Alphyn, Amryt Pharma, Beiersdorf, Brickell, Cutanea, Hoth, Lexington, Mustela, TopMD, NoblePharma | |
Speaker | Novartis, Sanofi Regeneron, CeraVe | |
Advisory Board | Almirall, Alphyn, Apogee, Aslan, Biofrontera, CeraVe, Krystal Biotech, Mustela, NobelPharma, Pfizer, Pierre Fabre, Sanofi Regeneron | |
Lisa Swanson, MD | Speaker | Abbvie, Arcutis, Galderma, Incyte, Johnson and Johnson, Lilly, Organon, Pelthos, Pfizer, Sanofi-Regeneron, Verrica |
Mercedes Gonzalez, MD | Advisor | Abeona, Alphyn, Amyrt, Arcutis, Cerave, Dermavant, Ely Lilly, Incyte, Noblepharma, Regeneron, Sanofi, Unilever, Inc, Verrica Pharmceuticals |
Consultant | Abeona, Alphyn, Amyrt, Arcutis, Cerave, Dermavant, Ely Lilly, Incyte, Noblepharma, Regeneron, Sanofi, Unilever, Inc, Verrica Pharmceuticals | |
Researcher | Abbvie, Arcutis, Dermavant, Ely Lilly, Krystal Biotech, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Verrica Pharmaceuticals, Amgen, Anterogen, Incyte, Neilsen Biosciences, Novartis | |
Speaker | Abbvie, Arcutis, Dermavant, Ely Lilly, Krystal Biotech, Pelthos Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Verrica Pharmaceuticals | |
Mohamad Goldust, MD | N/A | Nothing to disclose. |
Nanette Silverberg, MD | Advisor | Abbvie, Incyte, Lilly, Pelthos |
Consultant | Lilly | |
Speaker | Regeneron, Sanitizer, Pelthos, | |
Peter Lio, MD | Advisor | Alphyn Biologics, AbbVie, Almirall, Amyris, Apogee, Arcutis, ASLAN, Astria Therapeutics, Boston Skin Science, Bristol-Myers Squibb, Burts Bees, Castle Biosciences, Codex Labs, Concerto Biosci, ClearRx, Dermavant, Eli Lilly, Galderma, Kenvue, LEO Pharma, Lipidor, L'Oreal, Merck, Midwest Bioprocessing, Micreos, MyOR Diagnostics, Nektar Therapeutics, Nia Health, Pelthos Therapeutics, Phyla, Regeneron/Sanofi Genzyme, Sibel Health, Skinfix, Soteri Skin, Stratum Biosciences, Sun Pharma, Theraplex, Thimble Health, Topaz Biosciences,Inc., UCB, Unilever, Verdant Scientific, Verrica, Yobee Care |
Individual stocks and stock options | Alphyn Labs, Codex Labs, Concerto Biosci, Midwest Bioprocessing, Soteri Skin, Stratum Biosciences, Topaz Biosciences, Inc., Yobee Care, Verdant Scientific | |
Royalties or patent beneficiary | Theraplex AIM - Theraplex | |
Speaker | AbbVie, Arcutis, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay/L'Oreal, MyOR Diagnostics, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme, Verrica | |
Dorothy Caputo, MA, BSN, RN, President | N/A | Nothing to disclose |
Rebecca Lakofsky, BSN, RN | N/A | Nothing to disclose |
Michele Bielarski, RN (planner/reviewer) | N/A | Nothing to disclose |
AKH Inc Staff and Planners | N/A | Nothing to disclose |
Tarsus dba LiVDerm Staff and Planners | N/A | Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated. | ||
Disclosures
None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 10.75Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 10.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing
Credit being awarded: 10.75 ANCC contact hours
Physician Associates
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 10.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 10.75 AAPA Category 1 CME
- 10.25 AMA PRA Category 1 Credit™
- 10.75 ANCC
- 10.75 Attendance